The document discusses the CO-CTO trial (NCT04881812), which compares drug-coated balloon (DCB) angioplasty with traditional stenting for treating conditions adjacent to chronic total occlusions. It cites various studies evaluating the effectiveness and situations in which DCBs are beneficial, alongside considerations of patient outcomes such as major adverse cardiac events (MACE) and re-occlusion rates. Overall, the findings suggest specific scenarios where DCBs may offer advantages in managing coronary artery disease.

1. Drug-Coated Balloon Coronary Angioplasty
Versus Stenting for Treatment of Disease
Adjacent to a Chronic Total Occlusion.
Co-CTO Trial
NCT04881812
Alexander Nap
Amsterdam UMC
Netherlands

2. I, Alexander Nap DO NOT have a financial
interest/arrangement or affiliation with one or more
organizations that could be perceived as a real or
apparent conflict of interest in the context of
the subject of this presentation
Disclosure Statement of Financial Interest

3. SIZEDOES MATTER!
Claessen et al. JACC Interv 2011
MACE
length
diameter

4. DCB?
Courtesy B.BRAUN

5. WHY USE DCB?
BASKET-2-SMALL
DEBUT
Rissanen et al. Lancet 2019, Jeger et al. Lancet 2018
minimize DES burden (MACE, PHYSIOLOGY, CABG)

6. WHEN USE DCB?
Jeger et al. JACC Interv 2020

7. WHEN USE DCB?
Shin et al. JACC Interv 2023

8. WHEN USE DCB?
Shin et al. JACC Interv 2023

10. DCB IN CTO?
Walsh et al. JACC Interv 2020

11. Co-CTO - NCT04881812
pPCI
DIAMETER STENOSIS
(GAIN)
1 Y
DIAMETER STENOSIS
LATE LUMINAL LOSS
RE-OCCLUSION
MACE

12. DCB CTO ONLY?
Terashita et al. Cath Cardiovasc Interv 2023